Injectable Drug Delivery

Advances in technology for pens, auto-injectors, large volume pumps, patch pumps, needle-free, pre-filled syringes and other parenteral methods.

18-19 Mar 2020

GBP 1,499
EUR 2,099
USD 2,338

Book now

Conference Overview

Injectable drug delivery is considered one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, as well as the improved patient experience. The global injectable drug delivery market continues to grow and technology is advancing. This, coupled with the ever-changing regulatory requirements, means that it is imperative for companies to stay abreast of the latest developments and challenges within the industry in order to remain compliant, as well as gaining a competitive edge.

This seminar has been designed for all those working in the industry to discover the next generation of injectable drugs and devices and get an update on the latest trends, technologies and applications. Attending this event will provide a great opportunity to network with industry leaders, as well as like-minded professionals, to share common experience and best practice.

Attending this two-day seminar, presented by key industry experts, will:

  • Give you a valuable update on the advances in injection technology and drug delivery
  • Present you with up-to-date information on the latest market trends and opportunities for your organisation
  • Provide you with an opportunity to develop significant business partnerships

Newly updated programme for 2020 will be available in due course, please revisit this web page soon!


Book both

This meeting runs back-to-back with Pre-filled Syringes and there is a further £200/€280 discount when booked together with this programme.

To register on both events click HERE

To find out more call Customer Services on +44 (0)20 7749 4730 or e-mail

Previous Exhibitors Include:

3PInnovation logo

Harro Hofliger logo

Owen Mumford logo

ODD logo

Advanex logo

Exhibition opportunities are available. Please contact Customer Services on +44 (0)20 7749 4730
or contact us through our contact form.

Benefits in attending

  • Hear the latest trends in injectable drug delivery
  • Know what’s in development for large volume and patch pump technology
  • Keep abreast of market opportunities
  • Understand the latest technologies using parenteral methods
  • Clarify the importance of human factor studies and compliance monitoring
  • Comply with the latest regulatory guidance and standards
  • Meet other medical device and pharmaceutical professionals in the parenteral market

Who should attend

This conference will be of particular interest to:
Scientists and management in medical devices, pharmaceutical and biotechnology companies working in parenteral delivery. Personnel responsible for device programmes, product development, regulatory affairs and product lifecycle management will find this event beneficial. Previous delegates include: Directors, Senior Executives in R&D, Head of Device Departments, Combination Products Specialists, Drug Delivery Managers, Business Development Executives, Product Development Managers and those in Project Co-ordination and Marketing roles.

Programme day one

Chair’s welcome and introduction
Dr Gregory Berman

The evolving market for self-injection devices, differentiation through patient-friendly drug delivery devices

  • Market overview of parenteral drug delivery containers and devices
  • Evolving patient, market and regulatory expectations
  • Improved patient health and adherence through injectables
  • Emerging trends for novel drug delivery systems
  • Small volumes vs large volumes – where is it going?
  • Benefits of platform technology: faster time to market
    Dr Thomas Schönknecht

Assessing injection site pain

  • Understanding how to measure pain and tolerability during injection and how to interpret the results
  • Summary of recent clinical investigations of high-volume injections
  • Impact on the design and selection of wearable drug delivery devices
    Chris Muenzer

Discussion session

Challenges with high-volume and high-viscous drug formulations

  • Understand device and formulation landscape (mapping of potential design avenues not existing device landscape)
  • Selection criteria and considerations for both sourced or internally designed devices
  • Pitfalls and issues to be aware of with HVHV devices
  • Future gazing at device development trends
    Uri Baruch

Approaches to combination product control

  • Product Control Strategy Methodologies
  • How much control?
  • Where to control?
  • Challenges
  • Case Study – final product release tests
    Shruthi Vidyasagar

Discussion session

Pre-filled syringes over time

  • Evolution of processes and equipment
  • Evolution of components
  • Evolution of application and application systems
    Dr Andreas Rothmund

Using polymeric PDC technology to improve auto-injector design

  • The benefits of polymeric primary drug container (PDC) technology for the user and drug
  • PDC components configured freely, resolving issues typically seen with glass-based systems
  • How an integrated approach to device design reduces the impact on the user without compromise
  • Oval’s subcutaneous platform, Sumalen Ovali, and how it embodies this integrated philosophy to device design
  • A patient-centric device for delivery of Sumatriptan to migraine and cluster headache sufferers
    Sukie Whitehall

Discussion session

Connected needle-free drug delivery: innovative technology to differentiate your brand

  • The rapidly growing availability of monoclonal antibody and biologics therapies for chronic disease therapy
  • Why compliance and ease of use remain issues for these treatments
  • Review of recent attempts to connect drug delivery devices for biologics and lessons learned
  • Needle-free connected drug delivery systems
  • How interactivity and automated injection tracking could drive patient adherence and outcome
    Barb Taylor

Interactive panel discussion: opportunities for connectivity with hand-held injection devices
Moderator: Dr Gregory Berman
Panellists: Dr Thomas Schönknecht, Chris Muenzer and Barb Taylor

Networking drinks reception

Programme day two

Review of day one Dr Gregory Berman

Demand for large volume injectors for 2-10 ml injection volumes

  • Current trends for large volume injectors above 1ml
  • YpsoDose patch injector update
  • YpsoDose : usability and technical aspects
    Ian Thompson

Challenges of medical delivery in acute and chronic care settings – implications for delivery design

  • Clinical challenges for chronic versus acute care settings
  • Patient transition from acute care to step-down facilities; long-term care and home care settings
  • Commercial, ambulatory pump drug delivery systems; pros and cons of current devices
  • Opportunities for improving therapy
  • Wearable devices, patient-controlled analgesia (PCA), drug delivery via indwelling venous access devices (eg PICCs, CVCs, Midlines)

Discussion session

From the treatment chair to the sofa – innovative concept for wearable injection

  • New innovative approach to enable home care and address several market trends
  • Usability of a new dimension
  • Cutting-edge technology to benefit the patient
  • Opportunities for injectable drug delivery alternatives
    Tsachi Shaked

Update on the Ominpod device

  • How the technology works
  • Benefits to the patient
  • Personal diabetes management (PDM)
  • Continuous innovation for the diabetes community
    Dominic Hulton

Discussion session

The EU regulatory framework for injectable delivery systems

  • Classification – the importance of getting it right from the start
  • Implications of the new EU Medical Device Regulation (EU) 2017/745 and Article 117 for drug delivery systems
  • Essential considerations for injectable medicinal products
    Mark Chipperfield

Planned changes to the 11608 series of ISO standards and their implications on device design

  • How are large volume injectors different from infusion pumps?
  • Important changes proposed in the updates to the 11608 series
  • How these changes will impact on your device design
  • Verification of device performance
    Stephen Augustyn

Interactive panel discussion: opportunities with wearable and large volume injectors
Moderator: Dr Gregory Berman
Panellists: Ian Thompson and Stephen Augustyn

Chair’s closing remarks

End of seminar and refreshments


Andreas Rothmund

Dr. Andreas Rothmund is Qualified Person at Vetter Pharma-Fertigung in Ravensburg, Germany, an independent contract manufacturer specialised in the aseptic production of pre-filled application systems. He started his industrial career in 1985 as a lab manager. After two years he took over production responsibility for a German company specialised in eye drops and eye ointments, a position he held for nearly eight years.

He joined Vetter in 1994, where he has held several positions, including Head of Production for one of Vetter’s aseptic production units. He holds a degree in organic chemistry from the University of Constance, Germany.

Gregory Berman

Gregory Berman is an Independent Consultant and Director of Cantab Innovations Ltd. Previously he was Head of the Medical Group at Kinneir Dufort, an award-winning research, innovation, design and product development company, with over 30 years’ experience helping companies discover, create, develop and realise tangible new products, brands and experiences. He helps clients in the life-science, medical and healthcare sectors to develop products in complex situations, optimise life-science R&D and exploit technology strategically.

He led the design and development of SmartJect™; an autoinjector which automatically retracts the needle and was launched by J&J in 2010 with an important next-generation drug.
Worked with Chrono Therapeutics, helping to develop their SmartStop™ based device, the world’s first programmable, wearable transdermal smoking cessation therapy.
Participated in a detailed design review of an autoinjector being developed by a leading pharmaceutical company for a new drug.
Undertook the Voice of Customer study for a leading biopharmaceutical company, as the starting point for developing high volume parenteral delivery devices for lifesaving immunotherapies.

Undertook a technology survey for a company interested in needle-free, transdermal, micro-needle, electroporation and iontophoresis drug delivery devices.

Ian Thompson

Ian Thompson has been Vice President Business Development, Delivery Systems with Ypsomed AG since 1995. He has had a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990. Following the successful development and launch of a range of new pen and autoinjector custom products, Ypsomed Delivery Systems’ continues to focus on the development of next generation pen, autoinjector and bolus injector technologies.

Patrick Anquetil

Dr. Patrick Anquetil is Portal Instrument’s Chief Executive Officer. He brings more than 18 years of experience in nanotechnology, including extensive knowledge in the areas of cleantech, material science, and instrumentation.
From 2009 to 2012, he was co-founder and director of strategic and process planning for SynapDx Corporation, where he had responsibility for development of the company’s business and operational plans as well as securing $9 million in Series A funding. He began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing nanotechnology industry and equity research reports to hedge funds and portfolio managers. He holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard University, and a master’s degree from the ETH in Zurich and the University of Tokyo. His work has appeared in numerous peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC among others.

Neil Williams

Neil is the Head of Connected Health and Director of Front-End Innovation for Phillips-Medisize, based in Cambridge UK. Neil consults for BioPharma clients, innovating and executing strategies to enhance stakeholder engagement through connected devices and service design. He has over 22 years’ commercial experience covering medical devices, telemetry, digital imaging, clinical decision support, secure mobile working, patient engagement and health analytics for businesses including Philips Healthcare, Microsoft, Elsevier Health Sciences, Hospira, Map of Medicine and ZOLL. Prior to Neil’s commercial career he trained at Leicester University Hospitals in Operating Department Practice and was Faculty for numerous Advanced Life Support programs having qualified in the UK and United States.

Christopher Muenzer

Chris Muenzer is a Senior Device Technology Manager at Novartis in Basel, Switzerland. He has almost 20 years of development experience with a focus on drug delivery devices and has filed several patents in the field. At Novartis, Mr. Muenzer leads a team supporting injectable delivery systems for Novartis’ diverse portfolio of drugs. In addition to his work at Novartis, he is active on the ISO working group for injection devices. Mr. Muenzer holds a BSME from Carnegie Mellon University in Pittsburgh, Pennsylvania in the US.

Book now

18-19 Mar 2020
18-19 Mar 2020 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Advention Business Partners
  • Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
  • Alexion Pharmaceuticals Inc
  • Becton Dickinson
  • Biogen Idec Ltd
  • Bristol-Myers Squibb
  • Catalent Pharma Solutions
  • Elcam Medical
  • F. Hoffmann-La Roche Ltd
  • Flamel Technologies
  • Forteq Healthcare
  • Genentech Inc
  • Glide Pharmaceutical Technologies Limited
  • Grunenthal GmbH
  • Harro Hoefliger Packaging Systems Ltd
  • Haselmeier GmbH
  • Meridian Medical Technologies, a Pfizer Company
  • Nelipak bv
  • Novartis Pharma AG
  • PA Consulting
  • PDD GROUP Limited
  • Pfizer Cambridge
  • Rexam Healthcare La Verpilliere
  • Robert Bosch GmbH
  • Roche Diabetes Care AG
  • Salvus Technology Limited
  • Sortimat Technology GmbH & Co
  • Vetter Pharma International GmbH
  • West Pharmaceutical Services

Topics well selected. Good speakers and broadly based.

Stefan Gaul, Head of Strategic Product Management, Haselmeier AG

Very good and useful. Excellent.

Gajane Zurawska, Global Marketing Director, HTL-STREFA S.A.

Generally very good. We were well looked after. Venue excellent, management forum very professional. Needs more than just device suppliers in attendance.

Victoria Morgan, Director Segment Marketing, West Pharmaceutical Services

Well worth the time

David Haase, Senior Manager Device Development, Genentech

Very good

Roland Marshall, Account Manager, Owen Mumford Ltd

Good conference. Will most likely come again.

Thomas Mayer, Intl. Key Account Manager, Sonceboz SA


Mindy Katz, Product Manager, Sorrel Medical